secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001104659-25-106282
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel Q3 net income $27.9M, raises 2025 revenue guidance to $285-290M
---------------------------------------------------------------------

- Q3 net income $27.9M ($1.46 diluted EPS) vs $12.4M ($0.70) in Q3 2024.
- Total revenue $69.5M, record net product sales $64.1M (+65% YoY).
- Raises 2025 total revenue guidance to ~$285-290M (prior $270-280M); product sales $225-230M.
- TAVALISSE sales $44.7M (+70%), GAVRETO $11.1M (+56%), REZLIDHIA $8.3M (+50%).
- R289 Ph1b dose expansion underway; Lilly terminates CNS collaboration (60-day effect).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465925106282/0001104659-25-106282-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465925106282/tm2530133d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-106282

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer